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ABSTRACT
Fanconi anemia (FA) is a genome instability syndrome that is clinically
manifested by bone marrow failure, congenital defects, and elevated cancer
susceptibility. The FA pathway is known to regulate the repair of DNA
interstrand crosslinks in part through DNA homologous recombination (HR)
repair. Up to today 16 FA proteins have been discovered that may
participate in the common pathway. Cells that have mutations in the FA
genes are hypersensitive to DNA damaging agents and display chromosome
instability. A key regulatory event in the FA pathway is monoubiquitination
of FANCD2-FANCI heterodimer that is mediated by a multi-component E3
ubiquitin ligase complex called FA core complex. Current model suggests
that once the FANCD2-FANCI heterodimer is monoubiquitinated it relocates
to chromatin where it interacts with other key repair proteins to facilitate
DNA repair. More than 90% of the FA cases are presumed to be associated
with defects in the monoubiquitination reaction, suggesting the significance
of the modification in the pathogenesis of the disease. Despite the
significance, the molecular interplay between the FA core complex and the
FANCD2-FANCI heterodimer remains enigmatic. We are interested in the
assembly mechanism of the various FA subcomplexes into the core complex,
and we are actively investigating how the FANCD2-FANCI heterodimer is
vi

recruited to these putative subcomplexes. As the FA pathway is a crucial
determinant for cellular resistance to DNA damaging agents, there have
been hypotheses that disruption of this pathway may be beneficial in
enhancing chemosensitivity of certain cancer cells. In collaboration with Dr.
Cai’s chemistry lab, we will develop a screen platform to identify a small
molecules to interrupt the monoubiquitination reaction. Completion of these
studies will enhance the much-needed knowledge of the key enzymatic
reaction in the pathway, and perhaps the information can be used for
development of novel chemotherapeutic strategies.
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CHAPTER ONE: INTRODUCTION TO UBIQUITINATION

Ubiquitin as a Cellular Regulator
Ubiquitin is a small, globular protein that has 76 amino acids that gets
conjugated to other proteins and regulates the cell’s biological processes like
transcription, DNA repair, protein degradation, endocytosis, inflammatory
responses, and differentiation [1, 2]. Ubiquitin has seven lysine residues
(K6, K11, K27, K29, K33, K48, and K63) that can be connected to each
other in order to form a polymer. An ubiquitin polymer (polyubiquitin chain)
is formed by the creation of an isopeptide bond in between the ε-amino
group of an ubiquitin’s lysine and glycine 76 of another ubiquitin.
Monoubiquitin and polyubiquitin chains are conjugated to the substrate
protein’s lysine, specifically the ε-amino group, or to the protein’s extreme
N-terminus [3]. Proteins that interact and recognize ubiquitin have ubiquitin
binding domains (UBDs) within their structures [4]. There are over 20
different UBD families, with over 200 proteins that have been discovered to
have UBDs in their structures [5]. Ubiquitin is added to the substrate protein
by an ATP-dependent hierarchical cascade of reactions: An ubiquitin is
noncovalently adenylated to the C-terminus of the E1 activating enzyme as
an ubiquitin donor, this ubiquitin is then transferred to a cysteine in the E1;
1

this second ubiquitin forms a thiol ester bond with the E1 [2]. E1 then
transfers the ubiquitin to a cysteine residue of an E2 ubiquitin-conjugating
enzyme, this bond is a thioester bond [2]. E2 enzymes have a UBC
(ubiquitin conjugating) domain that is essential for the conjugation of
ubiquitin [6]. Once the E2 is charged it interacts with an E3 protein ligase
that is bound to the substrate to be ubiquitinated (figure 1).

Figure 1. Overview of the E1, E2, and E3 interaction for the ubiquitination of a
substrate. Ubiquitin is added to the E1 in an ATP dependent manner. The E1 then charges
the E2, which interacts with the E3 and ubiquitinates the substrate (Adapted from Hicke et
al., 2005 [1]).

E3 ligases can belong to two different families: RING (really interesting
new gene) E3 enzymes and HECT (homologous to the E6-AP carboxyl
terminus) domain E3 enzymes. The RING domain contains histidine and
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cysteine residues in specific patterns with zinc ions bound by them. The
HECT domain has two lobes formed of approximately 350 residues. E3s that
are from the HECT family interact with the ubiquitin charged E2 through
their N-terminus and their catalytic site is on the C-terminus [2, 7]. In the
human genome there are two E1 activating enzymes, over 40 E2 UBC
enzymes, and over 600 E3 ligases [6] (figure 2).

Figure 2. The hierarchy of the ubiquitin conjugating cascade. One E1 catalytic
enzyme can interact and charge several E2 ubiquitin-conjugating enzymes. Each E2 enzyme
can then interact with more E3 ligases (Adapted from Hicke et al., 2005 [1]).

Polyubiquitination vs. Monoubiquitination
A polyubiquitin chain of four ubiquitins or more on lysine 48 of a
protein will lead to its degradation by the 26S proteasome [8]. The 26S
proteasome contains 3 subunits: one 20S subunit and two 19S subunits. The
20S proteasome is a hollow cylinder composed of four rings that are stacked
on top of each other, with the active site facing the inside of the tube. The
proteins have to be denatured before entering the chamber through a
3

narrow opening on the ends of the 20S proteasome [9]. To each end of the
20S proteasome binds a 19S complex, this complex recognizes the
polyubiquitination signal, unfolds the targeted protein, and activates the 20S
proteasome for proteolysis [9] (Figure 3). Not every polyubiquitinated
protein is destined to be broken down by the proteasome. It is all subject to
the type of polyubiquitin chain, for instance polyubiquitin chains on lysine
residue 63 can activate kinases [10].

Figure 3. Protein proteolysis by the 26S proteasome after substrate
polyubiquitination. One E1 catalytic enzyme can interact and charge several E2 ubiquitinconjugating enzymes. Each E2 enzyme can then interact with more E3 ligases (Adapted
from Hicke et al., 2005 [1]).

Monoubiquitination is the addition of only one ubiquitin per lysine
residue to the protein. Some proteins can be monoubiquitinated on several
sites. One example of how monoubiquitination regulates proteins is by the
breakdown of plasma membrane proteins that can be triggered through
4

monoubiquitination, for example the monoubiquitination triggers the
endocytosis of the protein, which later gets degraded in the lysosome [11].
Another example is the ubiquitination on lysine residue 119 of histone H2A,
which can change the chromosome structure and the transcription of genes
(i.e. gene silencing) [12]. During DNA damage repair the protein
Proliferating Cell Nuclear Antigen (PCNA) gets monoubiquitinated by the E2
Rad6 and the RING E3 RAD18; this monoubiquitination leads to the
recruitment of several DNA polymerases to the site of the lesion for the
repair of the DNA [12]. Monoubiquitination of a protein can lead to different
outcomes: changing the localization of the protein, assembly or disassembly
of protein complexes, and altering the structure of the protein or the protein
complex [4].

Deubiquitinating Enzymes
The addition of ubiquitin can be reversed and this process is
dependent on deubiquitinating enzymes (DUBs). There are around 100
known DUBs in the human genome [12]. DUBs can be categorized into five
different families (four thiol ester proteases and a metalloprotease): the
ovarian tumor proteases (OTUs), ubiquitin-specific proteases (USPs), the
Josephins, ubiquitin C-terminal hydrolases (UCHs), and the zinc-dependent
metalloproteases [12]. The role of DUBs in the cell is almost as important as
5

that of the phosphatase. DUBs can inhibit proteolysis or promote it, they can
change the localization of a specific protein, remodel a protein’s structure,
and even directly interact with an E3 ligase thus regulating it [13].

6

CHAPTER TWO: INTRODUCTION TO FANCONI ANEMIA AND THE
FANCONI ANEMIA REPAIR PATHWAY

Clinical Aspects and Treatment of Fanconi Anemia
Fanconi anemia (FA) is an autosomal or X-linked genetic disorder that
causes chromosomal instability in the cell which leads to several congenital
defects and a high cancer incidence in FA patients. It has been estimated
that one in 300 people are carriers of a FA mutation while the disorder itself
is seen in one in 300,000 births [14]. Even though some patients have been
diagnosed at 48 years old, the median age for the diagnosis of FA in girls is
eight years and six point five in boys. In 2000, the median age for the death
of FA patients was 30, compared to 19 in 1990. This number has probably
increased due to medical advances which could have led to early diagnosis
and better therapies once the disease has been confirmed [15]. A higher
carrier frequency of 1:100 was found in Ashkenazi Jews, Afrikaaners, and
the Romani people in Spain (gitanos) [16]. The most common congenital
defect in FA patients is skin abnormalities (55%) followed by short stature
(51%) even though 25% to 40% of FA patients do not have any physical
abnormalities [15]. Bone marrow failure will usually appear during the
7

patient’s first ten years of life. 90% of FA patients have bone marrow
problems by the time they turn 40 years old, patients with FAcomplementation group C (FANCC) mutated have the highest incidence of it.
28% of FA patients that are 40 years old develop solid tumors, with females
having a higher incidence of them [17]. The most prevalent cancer in FA
patients is acute myeloid leukemia which is seen in at least 20% of FA
patients. The risk of a FA patient to develop acute myeloid leukemia is 800fold higher compared to a healthy individual [18]. Other cancers that can
affect FA patients are gynecological squamous cell carcinoma, neck and head
squamous cell carcinoma, esophageal carcinoma. FA patients also develop
tumors in the skin, brain, liver, and kidneys [19].
One of the diagnostic tests for Fanconi anemia is the chromosomal
breakage test done with an interstrand crosslinking (ICL) agent, usually
mitomycin C (MMC) or diepoxybutane (DEB). Cells from FA patients are
hypersensitive to ICL agents and accrue DNA damage very fast leading to
breaks in the chromosomes [20, 21]. Another diagnostic test for FA that is
done in conjunction with the DEB test is the assay of the monoubiquitination
of FANCD2 in the patient’s primary lymphocytes. If the monoubiquitination
of FANCD2 does not occur in these cells, the transfer of FA genes by
retroviral infection is performed, if the transcription of any of the FA proteins
rescues the monoubiquitination of FANCD2 then the diagnosis of FA can be
made [22].
8

Patients with FA receive androgen therapy in order to treat the bone
marrow failure but hematopoietic stem cell transplant is the main treatment
for bone marrow failure in FA patients, even though it does not treat the
high cancer incidence of FA patients. The chemoradiation used in the HSCT
can be detrimental for the FA patients due to the defective DNA repair in
their cells so a non-irradiation immunosuppressive technique is preferred for
the conditioning portion of the treatment [18]. Since FA patients cannot
undergo any type of chemotherapy or radiation for the treatment of cancer
they have to get regular check-ups in order to preclude the cancer before it
can develop [18].
Fanconi Anemia Pathway
The Fanconi anemia pathway integrates different repair pathways,
nucleotide excision repair (NER), translesion synthesis (TLS), and
homologous recombination (HR), in order to repair and resolve these lesions
in the cell’s DNA [23]. Up to this date there has been 16 proteins that have
been discovered to have mutations in FA patients (FANCA, FANCB, FANCC,
FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ, FANCL, FANCM,
FANCN, FANCO, and FANCQ). Out of the 16 FA proteins, eight of them make
up the FA core complex, which is activated upon DNA damage [24]. An
overview of the proteins of the FA core complex, FANCD2, FANCI, and other
key proteins of the FA pathway are discussed below (table 1).
9

Table 1. Summary table of the proteins involved in the Fanconi anemia pathway.
(Adapted from Crossan et al., 2005).

Protein

Other
names

Function in repair

Source

FANCA

Core complex; A-G-20 Subcomplex

[25]

FANCB

Core complex; B-L-100 Subcomplex

[25]

Core complex; C-E-F Subcomplex

[25]
[26]

FANCF

RAD51 interaction; homology search in HR
Core complex substrate; Recruits downstream
repair factors
Core complex; C-E-F Subcomplex; interacts with
FANCD2
Core complex; C-E-F Subcomplex

FANCG

Core complex; A-G-20 Subcomplex

[25]

Core complex substrate

[24, 25]

5' to 3' DNA helicase

[28]
[25]

ATM

Core complex; E3 Ring; B-L-100 Subcomplex
E2 of the FA pathway, monoubiquitinates
FANCD2
Interacts/stabilizes BRCA2
Core complex; Recruits FA core complex to site
of damage
Core complex; Recruits FA core complex to site
of damage
RAD51 homologue
Nuclease scaffold for XPF-ERCC1 and MUS81EME1
Phosphorylates FANCD2 and FANCI. Activates FA
pathway
Phosphorylates FANCD2 after IR

BRCA1

Recruits FANCD2 to γH2AX

[36]

RAD51

[30]

PCNA

Searches for homology on the sister chromatid
Stabilizes FANCD2; interacts with MRN complex
and BRCA1
Necessary for FANCD2 monoubiquitination

FAN1

5' flap endonuclease and 5' to 3' exonuclease

[35]

XPF-ERCC1

3' flap endonuclease; unhooks crosslinker

[39]

MUS81-EME1
MRN
Complex

Processes ICLs to DSBs
Stabilizes FANCD2 and localizes it to DNA
damage site

[40]

FANCC
FANCD1

BRCA2

FANCD2
FANCE

FANCI
FANCJ

BRIP1

FANCL
UBE2T
FANCN

PALB2

FANCM
FAAP24
FANCO

RAD51C

FANCP

SLX4

ATR

CtIP
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[24, 25]
[25, 27]
[25]

[29]
[30]
[25, 31]
[25, 31]
[32]
[33]
[34]
[35]

[37]
[38]

[41]

The Fanconi Anemia Core Complex
As stated above, eight of the 16 FA proteins (FANCA, FANCB, FANCC,
FANCE, FANCF, FANCG, FANCL, and FANCM) and four Fanconi anemia
associated proteins (FAAPs – FAAP16, FAAP20, FAAP24, FAAP100) form a
core complex [25]. This core complex acts as a multi-subunit E3 ligase, with
FANCL acting as the E3 catalytic ligase subunit. Even though the functions of
many of the FA core complex proteins are still unknown, studies have
suggested that there are sub-complexes within the FA core complex:
FANCB/FANCL/FAAP100 (B-L-100) which contains the E3 ligase unit FANCL
as previously stated, FAAP100 a 100kDa polypeptide which is thought to
stimulate FANCL [25, 42], and FANCB whose gene resides in the X
chromosome and gives the X-inheritance pattern to the disorder and it is
suspected to stabilize FANCM [31, 43]; FANCA/FANCG/FAAP20 (A-G-20)
which has been shown to bind to bind to chromatin and DNA through the
UBZ domain of FAAP20 and through the TPR repeats of FANCG, and FANCA
which has been found in 66% of all of FA patients [44];
FANCC/FANCE/FANCF (C-E-F) which is suggested to be the sub-complex
necessary for the physical interaction in between the FA core complex and
FANCD2-FANCI. FANCE has been shown to be the FA core complex substrate
adaptor and it interacts directly with FANCD2 [27], FANCC has been shown
to be mutated in 12% of all FA patients [44] , and the N-terminus of FANCF
has been proven to interact with the MM1 (FANCM motif 1) motif of FANCM
11

and it is suspected to act as a mediator that can interact with the other subcomplexes making it the central connector of the FA core complex [45].

FANCM and FAAP24
As stated previously, FANCM is also a protein of the FA core complex.
FANCM has DNA binding activity, it specifically binds to stalled replication
forks and as of this moment it is the only known protein in the FA core
complex with this capability, it has been shown that FANCM can bind doublestranded DNA (dsDNA) and single-stranded DNA (ssDNA) in vitro [45].
FANCM is homologous to the Hef protein (helicase-associated endonuclease
for fork-structured DNA) and has a Superfamily 2 (SF2) helicase domain that
is a DEAH helicase domain at its N-terminus and with FAAP24 part of the XPF
endonuclease family. On the C-terminus FANCM contains an excision repair
cross complementation group 4 (ERCC4) endonuclease domain [46]. The
DEAH helicase domain is the domain that contains the ATPase activity and
DNA binding properties of FANCM [47]. The C-terminus’ ERCC4
endonuclease domain is actually inactive due to some amino acid variations
in the catalytic section of FANCM’s ERCC4 compared to other proteins’ active
ERCC4 nuclease domains [48]. It is through the C-terminus that FANCM
interacts with FAAP24. FAAP24 (Fanconi anemia-associated protein of
24kDa) also contains an inactive ERCC4 domain that has affinity for ssDNA
[31]. It is speculated that together, FANCM and FAAP24, sense and
12

recognize stalled replication forks and direct the FA core complex to the site
of DNA damage during S-phase [49]. Both of them, FANCM and FAAP24,
contain an HhH (helix-hairpin-helix) motif in their C-terminus, this region
being essential for the binding to DNA in a sequence-nonspecific manner
[49].
FANCM has been shown to be phosphorylated by ATR after DNA
damage. The phosphorylation of FANCM intensifies its affinity to chromatin
[50]. On the other hand, hyperphosphorylation of FANCM during mitosis that
is induced by Plk1 leads to its inactivation, dissociation from the FA core
complex, and degradation, which explains why there is no active FA pathway
during mitosis [51]. After FANCM’s hyperphosphorylation event, β-TRCP
(part of the SCF E3 ligase that is active during mitosis) recognizes FANCM
and the serine residues of its DSGYNS sequence and triggers the
degradation of FANCM [51].
Interestingly, FANCM links Bloom’s Syndrome (BS) and FA by
interacting with RM1 and topoisomerase IIIα of the Bloom complex [45]. It
has been shown that FANCM interacts with these proteins through its MM2
motif, and that this motif is indispensable for its interaction with the FA core
complex, through FANCF as it was stated previously, and the
monoubiquitination of FANCD2 [45].
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FANCL and UBE2T
FANCL is another protein of the FA core complex that has a specific
activity within the complex. FANCL acts as the E3 ubiquitin ligase of the FA
pathway [52]. FANCL contains a RING domain at its C–terminus, it is
through this domain that it interacts with UBE2T [6] (figure 4). The RING

C

N

N
C
Figure 4. Crystal structure of UBE2T and the RING domain of FANCL. Ribbon model
of the crystal structure of UBE2T in blue and the RING domain of FANCL in purple which
interacts with UBE2T. Their termini are labeled for clarification. PDB file downloaded from:
http://www.rcsb.org/pdb/explore.do?structureId=4CCG - 3D image created with SwissPdbViewer 4.1.0.

domain of FANCL contains a slight different amino acid sequence that is seen
in most RING domains; FANCL’s RING domain has two zinc atoms that are in
between four cysteine residues, one histidine residue, and three cysteine
residues (compared to three cys, one his, and four cys)[6]. On the N14

terminus FANCL contains three WD-40 domains that are arranged in a RWDlike domain. The WD-40 domains have been shown to stimulate the activity
of FANCD2 and to increase the monoubiquitination of FANCD2 [53]. UBE2T is
the only known E2 of the FA pathway, it contains a UBC-homology domain
that catalyzes the ubiquitination event, and its active site is Cys86 where E1
transfers a ubiquitin molecule to [29]. UBE2T has also been shown to
become monoubiquitinated at Lys91 this monoubiquitination serves as a
negative auto-regulation event that inactivates UBE2T and it is enhanced by
FANCL [29].

FANCD2 and FANCI Structure
FANCD2 is the key protein the FA pathway and its monoubiquitination
is the main event of the FA pathway. 5% of FA patients have a FANCD2
mutated and the incidence of a FANCI mutation is even lower [21]. Most
studies use the monoubiquitination of FANCD2 in order to study whether the
FA core complex is functional or not. Monoubiquitination of FANCD2 occurs
during S-phase and after the cell has been exposed to DNA damaging agents
like MMC, cisplatin, radiation (UV), and ionizing radiation [44]. FANCD2 and
FANCI form a heterodimer complex that is phosphorylated by ATR (ataxia
telangiectasia and Rad3-related) and monoubiquitinated by the FA core
complex [34]. The crystal structure of the FANCD2-FANCI complex has been
purified (figure 5).
15

FANCD2 has only four domains that have been discovered up to date.
Montes de Oca et al. demonstrated that FANCD2 has a span of 24 amino
acids at its C-terminus that is necessary for ICL repair but not
monoubiquitination or chromatin localization after DNA damage. This
segment is conserved in rodents and humans and it has been named EDGE
due to the amino acid sequence within it [54]. FANCD2 also contains a PIPmotif (PCNA-interacting protein) in its middle section [38]. It is through this
motif that it physically interacts with PCNA, they both co-localize to the
nucleus after DNA replication has been inhibited [38]. The PIP-motif and the
interaction in between FANCD2 and PCNA are both necessary for the
monoubiquitination of FANCD2 following DNA damage but not for FANCD2
localization to chromatin, its phosphorylation by ATR, or its interaction with
FANCE [38]. In its N-terminus FANCD2 has a CUE (coupling of ubiquitin
conjugation to endoplasmic reticulum degradation) UBD [55]. This domain
has been shown to be necessary for the interaction in between FANCD2 and
FANCI and their co-localization to chromatin [55]. FANCD2’s CUE UBD
interacts with ubiquitin on lysine523 of FANCI in a noncovalent way. This
interaction is dispensable for the monoubiquitination of FANCD2 but it
somehow does stabilize it and prevents it from being degraded by the
proteasome [55]. Further down the N-terminus FANCD2 has a NLS (nuclear
localization signal) that is necessary for the monoubiquitination of FANCD2,
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FANCD2 and FANCI movement into the nucleus, and for the repair of ICL on
the cell’s DNA [56] (figure 6).
FANCD2 has been shown to have affinity for dsDNA ends and Holliday
junctions, one of the only known biochemical properties FANCD2 has [55].
FANCD2 and FANCI interact with each other through a ~560 amino acid
region along the middle of both proteins in an antiparallel manner with their
ends remaining free [34] (figure 5). FANCD2 monoubiquitination site is
lysine 561 and FANCI monoubiquitination site is lysine 523, interestingly
these sites are in the interface of the two proteins but their side chains are
still solvent exposed even though the channels are too small for UBE2T
interaction [34]. FANCD2 and FANCI both are comprised of mainly alphahelices that are organized in pairs antiparallel to each other that form αsolenoids [34]. FANCD2 and FANCI do not share homology in their whole
structure but mainly through the solenoid segments. Solenoid 2 of both
proteins share the most homology, this is also the segment where both
proteins have their monoubiquitination sites [34]. It is known that the FA
core complex and the monoubiquitination of FANCD2 are necessary for the
monoubiquitination of FANCI but functional and monoubiquitinated FANCI is
not necessary for FANCD2 monoubiquitination or essential for DNA repair
[57]. What is still not known about these two proteins is whether they come
as a heterodimer complex to the FA core complex or as separate proteins. It
is also not known what the monoubiquitination of the proteins does to the
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complex, it might separate or bring together the proteins, or just change the
complex conformation, this issue is discussed in more detail further down.

C
N
N

C
Figure 5. Crystal structure of the FANCD2 and FANCI complex. Ribbon model of the
crystal structure of FANCD2 in green and the FANCI in pink. Their termini are labeled for
clarification. PDB file downloaded from:
http://www.rcsb.org/pdb/explore.do?structureId=3s4w - 3D image created with SwissPdbViewer 4.1.0.

Figure 6. Schematic depiction of the domains of FANCD2. FANCD2’s NLS is at the Nterminus, followed by the CUE domain around amino acid 222 and the PIP box, lysine
residue 561 that undergoes monoubiquitination is highlighted, and at the C-terminus is the
EDGE domain (Adapted from Boisvert et al., 2014 [56]).
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FANCD2 Regulation and Interacting Proteins
On top of being monoubiquitinated, FANCD2 and FANCI are also
phosphorylated. As stated before the phosphorylation of both is dependent
on ATR [34]. FANCI contains six S/TQ motifs that are phosphorylated; two of
the most important sites are residues serine 558 and serine 561, both of
them are close to lysine 523 where FANCI gets monoubiquitinated [57]. The
phosphorylation of FANCI is necessary for the monoubiquitination of FANCD2
and its own monoubiquitination, making it a key step in activating the FA
pathway [58]. Another key step in activating the FA pathway through
FANCD2 monoubiquitination is the phosphorylation of FANCD2 by ATR on
threonine 691 and serine 717 [56]. Sareen et al. have demonstrated that
the phosphorylation of FANCI leads to the dissociation of FANCD2 and FANCI
and that without it FANCD2 does not become monoubiquitinated nor does it
localize to chromatin [59]. The results of Sareen’s work suggest that the
FANCD2-FANCI complex is the inactive form of the proteins and that they
can perform their functions in the DNA damage repair only after they have
dissociated from each other. This model proposed by Sareen et al. would
justify the size of the small channels that are around the ubiquitination sites
when FANCD2 and FANCI are in a complex since the phosphorylation event
and the dissociation of the proteins would leave the necessary lysine
residues readily available for monoubiquitination by UBE2T [56].
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In addition, FANCD2 can get phosphorylated by ATM (ataxia telangiectasia
mutated) on serine 222 in response to ionizing radiation (IR) in order to
activate the S-phase checkpoint and it is not dependent on FANCD2
monoubiquitination [35]. ATM phosphorylation of FANCD2 is not necessary
for its monoubiquitination like phosphorylation by ATR is. Foci formation, and
MMC sensitivity are also not dependent on ATM phosphorylation since ATM (/-) cells still see an increase of FANCD2 monoubiquitination, FANCD2 foci
formation, and MMC resistance [35, 54].
After FANCD2 gets monoubiquitinated by the FA core complex and
UBE2T, it co-localizes to chromatin [54] where it interacts with several
proteins. It is speculated that the role of FANCD2 in the DNA damage
response is to act as a regulator and a landing pad for other downstream
proteins. Garcia-Higuera et al. have seen co-localization of
monoubiquitinated FANCD2 and BRCA1 (breast cancer associated 1) after
DNA damage during S-phase [36]. The interaction of BRCA1 with
monoubiquitinated FANCD2 is an indispensable step for the recruitment of
FANCD2 to γH2AX [60]. H2AX gets phosphorylated on serine 139 by ATR
when stalled replication forks form after UV damage and as a result of this,
monoubiquitinated FANCD2 relocates to the site of damage on the chromatin
[60].
BRCA2 (breast cancer associated 2), known as FANCD1, also interacts
with FANCD2 [26]. BRCA2 and FANCD2 interact through the C-terminus of
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BRCA2, and this interaction is necessary for the co-localization of FANCD2
and BRCA2 to chromatin, but not for the foci formation of the two proteins
[26]. It is important to point out that the monoubiquitination of FANCD2 is
necessary for these interactions since the interaction of the two happens
once FANCD2 has been targeted to chromatin [26]. After BRCA2 has been
loaded onto the chromatin with the help of FANCD2 it stabilizes the
replication fork and it mediates RAD51 foci formation on ssDNA after DNA
damage [61, 62]. RAD51 is a homologue of RecA that is required for
homology directed repair (HDR), it co-localizes with BRCA2 after the cell has
been exposed to IR and during S-phase, and with FANCD2 during S-phase
[63]. RAD51 binds to processed ssDNA forming a nucleoprotein filament and
searches for homology in the sister chromatid in order to repair the
damaged DNA [30].
As stated before another protein that interacts with FANCD2 is PCNA,
the details of the interaction were discussed in the previous section. It is
important to point out though that the monoubiquitination of PCNA by
RAD18-RAD6 on lysine 164 is necessary for the monoubiquitination of
FANCD2, making RAD16-RAD6 another ubiquitin ligase that regulates
FANCD2, even though in this case is in an indirect manner [56].
CtIP (CtBP-interacting protein) is another protein that has been shown to
interact with FANCD2 in a BRCA1 dependent manner by Yeo et al. CtIP has
been reported to work in a DNA damage independent manner to stabilize
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FANCD2 [37]. CtIP has also been known to interact BRCA1 in a complex and
with MRE11 from the MRN (MRE11/RAD50/NBS1) complex to moderate DNA
end resection during HR and to promote HR repair [37]. FANCD2 interacts
with CtIP on stalled replication forks and together they suppress new
replication origins from starting and they promote the restart of the
replication fork [37]. MRE11/RAD50/NBS1 have also been shown to interact
with FANCD2 during S-phase, this interaction stabilizes FANCD2 and MRE11
is crucial in the localization of FANCD2 to the DSBs [41].

Fanconi Anemia Downstream Factors
FANCJ, also known as BRIP1 (BRCA1 interacting protein 1) is a DNA
helicase, with 5’ to 3’ polarity, that interacts with BRCA1 during the repair of
DSBs and it co-localizes with BRCA2 and RPA in the DNA repair structures.
In addition, FANCJ has been shown to be a tumor suppressor protein that is
regulated by the E2F/Rb pathway [28]. FANCJ has been shown to be
functional in cells that lack a functional FANCD2 demonstrating that FANCJ
acts either downstream or parallel to FANCD2 but its role in the repair of
ICLs is not known yet.
FANCN also termed PALB2 (partner and localizer of BRCA2) is a protein that
interacts with BRCA2 in order to localize it to the nuclear matrix, stabilize it
in its nuclear repair structure, and promote its activity in the nucleus for the
repair of damaged DNA [30].
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Fanconi Anemia Deubiquitinating Complex
In order to inactivate FANCD2 and FANCI and to terminate the DNA
repair FANCD2 and FANCI need to be deubiquitinated. This task is performed
by the DUB complex USP1-UAF1 (ubiquitin-specific protease 1 and USP1associated protein 1) [56]. UAF1 is an activator of USP1 and it interacts with
the SLIM (SUMO-like domain-interacting motif) of FANCI through its Cterminus where it has two SUMO-like domains, it is believed that this
interaction is the one that connects the USP1-UAF1 complex to FANCD2 and
FANCI [56].

Fanconi Anemia Pathway Mechanism
Homologous recombination is one of the many mechanisms that a cell
has in order to ensure that there is no DNA damage. HR is employed by the
cell in order to fix DSBs, damaging deletions, and ICLs. HR is also activated
by the cell to maintain telomeres, preserve replication forks, and during
meiosis I chromosome segregation [64]. Since the FA pathway is used to
repair ICLs, the focus will be on the use of mainly HR for the repair of ICLs.
If the DNA of the cell is damaged during S-phase, FANCM and FAAP24
together recruit the FA core complex to the site of damage [33]. The FA core
complex and UBE2T monoubiquitinate FANCD2 and FANCI, leading to their
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activation and localization to the chromatin, most likely they localize
independently of each other [21]. Once activated, FANCD2 interacts with
PCNA, BRCA2, and RAD51 as stated previously. Activated FANCD2 also
recruits FAN1 (Fanconi anemia-associated nuclease 1), a 5’ flap
endonuclease and an exonuclease with a 5’-3’ polarity, to the site of damage
[35]. Another protein that is recruited by FANCD2 is FANCP (also known as
SLX4). FANCP itself acts like a nuclease scaffold that interacts with the
endonucleases XPF-ERCC1 and MUS81-EME1 [65]. XPF-ERCC1 is a 3’ flap
endonuclease that unhooks the ICL from one of the strands of the replicating
DNA strand [39]. MUS81-EME1 is a structure specific endonuclease that
processes stalled replication forks due to ICLs into DSBs [40]. Once these
endonucleases are recruited to the site of the ICL they unhook the crosslinker from the template DNA strand. While the complimentary strand gets
repaired through TLS by REV1 and Pol ζ, the leading strand, now with a
DSB, gets repaired in a RAD51-dependent manner through HR [33]. The
cross-linker on the complimentary strand is removed by NER. In order to
inactivate the pathway and terminate the repair the complex USP1-UAF1
deubiquitinates FANCD2 and FANCI [33] (figure 7).
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Figure 7. Depiction of the removal of an ICL in a replication fork by the Fanconi
anemia DNA repair pathway. Once a cross-linker creates the ICL FANCM and FAAP24
recognize the lesion and recruit the FA core complex, at the same time the damage
activates ATR to phosphorylate FANCI. Once it is recruited the FA core complex and UBE2T
monoubiquitinate FANCD2 and FANCI. The two proteins then localize to the site of damage
where FANCD2 recruits several endonucleases and exonucleases to remove and unhook
the cross-linker. One of the strands is repaired by TLS polymerases. The other strand now
has a DSB which is repaired through HR by RAD51/FANCD1 and other FA proteins
(Adapted from Kim et al., 2012 [33]).
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CHAPTER THREE: CO-RECRUITMENT OF THE FANCD2-FANCI
HETERODIMER TO THE FA E3 LIGASE COMPLEX PROMOTES DNA
REPAIR

Rationale
FANCD2 is a 1471 amino acid molecule that is involved in the key
regulatory step of the DNA repair pathway Fanconi anemia. The FA pathway
repairs ICLs after the cell has been exposed to cross-linking agents and
during S-phase [55]. The activation of the FA pathway occurs when the FA
core complex, made up of eight FA proteins and four FA associated proteins
(FANCA, -B, -C, -E, -F, -G, -L, -M, FAAP16, -20, -24, and -100), and the E2
enzyme UBE2T monoubiquitinates FANCD2 and FANCI; FANCD2 and FANCI
form a heterodimer [27]. . A central regulatory event in the FA pathway is
monoubiquitination of FANCD2 and FANCI. Monoubiquitinated FANCD2 is
thought to trigger its association with other DNA repair proteins such as
RAD51, BRCA1, BRCA2, FAN1, and FANCP [55]. The monoubiquitination of
FANCD2 and FANCI is thought to be defective in more than 90% of all of FA
cases, which shows how important this key step is in the maintenance of the
cell’s genome through the FA pathway [27]. There is also evidence that
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FANCD2 has monoubiquitin-independent functions, such as recruitment of
BLM proteins to chromatin [66, 67]. FANCD2 also localizes to fragile sites of
damaged chromosome during mitosis, although its exact function there is
unclear [68]. Therefore the interplay between FANCD2 and the FA E3 ligase
complex (the FA core complex) must be precisely regulated in order to
dictate the differential functions of FANCD2. Ours and previous reports
suggested that FANCE is the essential component of the FA core complex
and for the FANCD2 and FANCI monoubiquitination [27]. The precise
biochemical reactions that involve FANCE, the rest of the FA core complex,
and FANCD2-FANCI heterodimer is yet to be elucidated. Better and precise
understanding of this key E3-substrate reaction in the DNA repair pathway
will contribute to the ubiquitin biology in general, as well as designing
potential chemosensitizing strategies that can target the FA pathway in
tumors. FANCD2 has been shown to interact with the FA core complex
through FANCE which is part of the C-E-F subcomplex of the FA core
complex [25, 27]. Due to the important role of FANCD2 in the repair of ICLs
we investigated the FANCE-interaction region of FANCD2. A better
understanding of how FANCD2 interacts with the FA core complex to be
monoubiquitinated will help in finding the cure for FA. In addition, gaining
insight into the regulation of the FA pathway will aid in the design of
therapeutic treatments for cancers that have increased DNA repair
pathways.
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Experimental Design and Methods
Cell Survival Assay
The patient derived PD-20 cell line (a FANCD2-deficient cell line) and
the complemented PD-20-Flag-FANCD2 cell line were seeded in triplicates in
12-well plates. MMC was added at a final concentration ranging from 0nM to
20nM. After the addition of MMC the cells were incubated for 7 days, and the
surviving cells were then fixed with fixation solution (10% methanol + 10%
glacial acetic acid) for 15 minutes. After fixation the cells were stained with
staining solution (5 g of crystal violet dissolved in 500 mL of methanol) at
room temperature for 10 minutes. The staining solution was then rinsed with
deionized water and the plates were left to dry overnight. Once the plates
were dry 300 µL of Sorenson’s buffer (14.705 g of 0.1 M sodium citrate, pH
4.2 + 250 mL of 50% ethanol + 200 mL of nanopure water) were added to
each well and the plates were placed on the shaker for 15 minutes. 150 µL
from each well was then transferred to a 96-well microplate. The amount of
purple in each well was read with a Biotek plate reader at a wavelength of
590 nm.

Yeast Two-hybrid Analysis
Human FANCD2 cDNA and FANCI were cloned into Matchmaker™ GAL4
Two-Hybrid System 3 vector PGBKT7 (Clontech) which contains the DNA29

binding domain (DBD). Human FANCE cDNA and human FANCI cDNA were
cloned into Matchmaker™ GAL4 Two-Hybrid System 3 vector PGADT7
(Clontech) which contains the activation domain (AD). Site-directed
mutagenesis of FANCD2 was achieved using pGBKT7-FANCD2 as a template
(except the F48P-L51P double mutant, the pGBKT7-F48P-FANCD2 mutant
was used as a template in this case) and the following primers for each point
mutant: D19P: 5’-T AAA GAG AGC CTG ACA GAA CCT GCC TCC AAA ACC
AGG AAG-3’, F48P: 5’-GAA AAT GAC AGC ATC CCT GTA AAG CTT CTT AAG3’, V49P: 5’-GAA AAT GAC AGC ATC TTT CCA AAG CTT CTT AAG ATA TCA
GG-3’, L51P: 5’-GAC AGC ATC TTT GTA AAG CCT CTT AAG ATA TCA GG-3’,
L51A: 5’-GAC AGC ATC TTT GTA AAG GCT CTT AAG ATA TCA GG-3’, and
F48P-L51P: 5’-GAC AGC ATC CCT GTA AAG CCT CTT AAG ATA TCA GG-3’.
The constructs were then transformed into the yeast strain AH109 by
following the Small-Scale LiAc Yeast Transformation Procedure in the
Clontech Yeast Protocols Handbook (PT3024-1). In order to select for
transformation the transformants were plated on selection media lacking
leucine (pGADT7) and/or tryptophan (pGBKT7), depending on which plasmid
they were transformed with. For the interaction plates the transformants
were spotted in triplicates in 10-fold serial dilutions on media that was
lacking leucine, tryptophan, and histidine; this media also contained 3 mM of
30AT and 20 µg/mL of X-α-gal. In order to check for protein expression the
proteins were extracted from the yeast by using the TCA method described
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in the Clontech Yeast Protocols Handbook (PT3024-1). The protein extracts
were then run in their appropriate percentage SDS-gel and blotted with
either DBD GAL4 antibody or AD GAL4 antibody (Santa Cruz). FANCE protein
expression western blots were blotted with FANCE antibody courtesy of the
Fanconi anemia Foundation.

FANCD2 INTERACTS WITH FANCE THROUGH THE N-TERMINUS OF
FANCD2
To identify which region of FANCD2 is necessary for the interaction
with FANCE we used the crystal structure of FANCD2 and a disorder
probability software to plan the different truncations that would be tested in
our yeast-two hybrid assay (figure 8). The crystal structure was taken into
consideration in order to not disrupt a helix or a beta-sheet and to pick an
amino acid that was conserved in several species.

Figure 8. Disorder probability diagram of FANCD2 and its secondary structure. The
disorder probability diagram shows the disordered areas in red while the orders areas are in
blue. The secondary structure diagram shows helices in red, coils in a gray line, and beta
strands as yellow. Disorder probability and secondary structure diagrams were created in the
RCSB PDB website: http://www.rcsb.org/pdb/protein/Q80V62

We first cloned FANCE into the pGADT7 vector and transformed it into
our AH109 yeast strain; the expression of FANCE was then confirmed by
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western blotting (anti-FANCE). Then we cloned full length wild-type FANCD2
into the pGBKT7 vector and transformed it into the AD-FANCE yeast
transformant, its expression was also confirmed by western blotting (antiDBD). After we confirmed that our yeast-two hybrid worked (figure 9) we
cloned a FANCD2 truncation that was missing the last 279 amino acids
(FANCD2-ΔC279) into the pGBKT7 vector. This truncated FANCD2 interacted
with FANCE in our yeast-two hybrid assay thus suggesting that the Cterminus of FANCD2 is dispensable for the interaction with FANCE (figure 9).
In order to narrow down our search we created several more truncations
that were cloned into the pGBKT7 vector and then transformed into the ADFANCE yeast transformant. Their interactions were then tested in the yeasttwo hybrid assay (figure 10).

Figure 9. Summary of FANCD2 truncations. These truncations were engineered in
order to test the interaction in between FANCD2 and FANCE the yeast-two hybrid assay.
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From the results from the yeast-two hybrid assay we could determine
that it was the N-terminus of FANCD2 that was necessary for the interaction
with FANCE since FANCD2-ΔN51 failed to interact with FANCE and FANCD2ΔN26 interacted with FANCE (figure 10).

Disordered Region of FANCD2 is Not Required for the FANCD2
Interaction with FANCE
Once we determined that the N-terminus of FANCD2 was necessary for
the interaction of FANCD2 with FANCE we decided to change Asp19 for a
proline residue in order to create the FANCD2-D19P point mutant. We chose
to replace the selected amino acids with proline instead of other amino acids
because proline is usually excluded from alpha helices and beta sheets due
to the bulkiness of its side chain [69, 70]. We picked this specific residue
based on a helical propensity analysis done on the disordered N-terminal
region of FANCD2 (figure 11) [71, 72]. The logarithm that was used to
predict the helical propensity of the region predicts three regions where a
helix could form. Since we were interested in the disordered region Dr.
Schmidt suggested we mutate Asp19 since it was the residue that would
disrupt the most probable helix in the disordered region (figure 11). We then
performed point-mutagenesis on the full wild-type FANCD2 that we had
previously cloned into our pGBKT7 vector and cloned it into the AD-FANCE
expressing yeast that we had previously transformed. FANCD2-D19P did
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interact with FANCE in our yeast two hybrid system (figure 12). These
results led us to the conclusion that FANCD2-D19P does not disrupt the
interaction of FANCD2 with FANCE (figure 12). …

......

A.
A.

.....

B.

Figure 10. The N-terminus of FANCD2 contains the epitope for its interaction
with FANCE. A. FANCD2-ΔN26 and FANCD2-N502 interact with FANCD2, while
FANCD2-ΔN51, FANCD2-ΔN238 do not in our yeast-two hybrid analysis. B. Expression
of proteins in the transformants for the yeast-two hybrid analysis.
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Figure 11. Helical propensity prediction of the first 100 residue FANCD2. Graph
depicts the helical propensity of the first 100 amino acids of FANCD2 [71, 72]. Amino
acid Asp19 resides in the disorder region of FANCD2 and performing point mutagenesis
and changing it to proline would disrupt this probable helix. Analysis provided by Dr.
Kristina Schmidt, USF.
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FANCD2 Leucine 51 is Required for the Interaction of FANCD2 and
FANCE
In order to find more amino acids that could be potentially necessary
for the interaction of FANCD2 with FANCE we provided Dr. Daughdrill from
CMMB with the crystal structure and the amino acid sequence of FANCD2.
Dr. Daughdrill suggested that we try several amino acids in the N-terminus
of FANCD2. From those that he suggested we selected three to mutate and
test how they affected their interaction of FANCD2 with FANCE (figure 13).
Just like before, the selected amino acids were changed to proline residues:
phenylalanine 48, valine 49, and leucine 51. Since FANCD2-F48P was the
A.
A.

B.
A.

Figure 12. FANCD2-D19P does not disrupt the interaction with FANCE. A. FANCD2D19P does not disrupt the interaction with FANCE in our two-hybrid yeast assay. FANCD2D19P grew just like WT-FANCD2 in the selection media. B. Expression FANCD2-D19P and
AD-FANCE in the transformants for the yeast-two hybrid analysis.
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first point mutant to be cloned into the pGBKT7 plasmid, we decided to also
try a double-point mutant that was created using FANCD2-F48P as a
template. The second residue that was mutated in the FANCD2-F48P
construct was leucine 51. Once we confirmed the point mutations by DNA
sequencing we transformed each one of them into the AD-FANCE yeast that
we had previously transformed. FANCD2-F48P and FANCD2-V49P did not
disrupt the interaction of FANCD2 with FANCE. However, FANCD2-L51P and
FANCD2-L51P-F48P did disrupt this interaction (figure 14). These results led
us to the conclusion that FANCD2’s leucine 51 is an indispensable amino acid
for the interaction with FANCE.

Figure 13. Selected amino acids for FANCD2 point-mutagenesis. Some of the amino
acids that Dr. Daughdrill suggested to mutate. The amino acids can be seen in the Nterminal helix of FANCD2 with the N-terminus being at the top and the growing peptide at
the bottom of the figure. PDB downloaded from:
http://www.rcsb.org/pdb/explore.do?structureId=3s4w - 3D image created with SwissPdbViewer 4.1.0.
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Figure 14. FANCD2-L51P and FANCD2-L51P-F48P disrupt the interaction with
FANCE. A. FANCD2-F48P and FANCD2-V49P do not disrupt the interaction of FANCD2
with FANCE. FANCD2-L51P and FANCD2-F48P-L51P disrupt the interaction of FANCD2 with
FANCE B. Expression FANCD2-F48P, V49P, L51P, F48P-L51P and AD-FANCE in the
transformants for the yeast-two hybrid analysis.
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FANCD2 Point Mutants Do Not Disrupt the Interaction in Between
FANCD2 and FANCI
We wanted to make sure that the FANCD2 point mutants did not
interrupt the interaction in between FANCD2 and FANCI. In order to do this
we cloned FANCI in to the pGADT7 vector and transformed into the AH109
yeast; we tested the expression of AD-FANCI by western blot (anti-AD). We
then transformed the AD-FANCI expressing yeast with either wild-type
FANCD2 or the FANCD2-F48P and FAND2-L51P point mutations. Neither
FANCD2-F48P nor FANCD2-L51P disrupted the interaction in between FANCI
and FANCD2 in our yeast-two hybrid assay (figure 15). These results
suggest that leucine 51 is not necessary for the interaction in between
FANCD2 and FANCI.

Conclusion and Future Directions
The physical and functional interplay among FANCD2, FANCI, and the
FA core complex is still not clearly understood. Our results suggest that
FANCD2 interacts with FANCE of the FA core complex through its N-terminus
and that leucine 51 is critical in this interaction (figure 16 and figure 17).
FANCD2’s leucine 51 is also conserved across species (figure 18).
The interaction assay in yeast used here must be validated in either
human cells using co-immunoprecipitation assay, or using purified proteins.
39

A.
A.

B.
A.

Figure 15. FANCD2-L51P and F48P do not disrupt the interaction with FANCI. A.
FANCD2-F48P and FANCD2-L51P do not disrupt the interaction of FANCD2 with FANCI in this
yeast-two hybrid assay. B. Expression FANCD2-F48P, L51P, and AD-FANCI in the
transformants for the yeast-two hybrid analysis. FANCD2 runs smaller in this blot because
FANCD2-ΔC279 was used for this yeast-two hybrid assay.

We are currently making attempts to generate purified FANCD2-FANCI
complex, using Bac-to-Bac insect cell system. Our current work is to
determine the effect of the mutation we found (e.g. L51P) in a relevant cell
culture system. We are currently working to generate a FANCD2-null
patient-derived PD-20 cell line that stably expresses wild-type and the
mutant counterpart of FANCD2 using a lentiviral system.
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This complementation system can be used for validating the effects of
mutations on FANCD2-FANCI monoubiquitination, foci formation,
chromosome breakage rate, and cellular sensitivity to Cisplatin or MMC
(figure 19). We hypothesize that the L51P mutant will behave as, or close to,
FANCD2-null, based on the lack of interaction with FANCE. However there is
a possibility that it is not the case; L51P mutant may rescue the FANCD2 null
phenotype only to a certain degree. This outcome would suggest that
FANCD2 clearly has functions independently of its interaction with FANCE
and possibly with the FA core complex. Indeed, recruitment of BLM protein
to chromatin is mediated by FANCD2, but it may be independent of its
monoubiquitination status [66, 67]. In addition, a series of three papers
recently suggested that FANCD2 has a role in recruiting CtIP, an
exonuclease that plays essential role in DNA double strand end resection
during the HR repair; however, there appears to be a conflicting information
as to whether monoubiquitination is essential for this process. Our
complementation system may be able to dissect the functions of the FANCD2
monoubiquitination that contribute to the field.
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Figure 16. Proposed model of the interaction in between FANCD2 and FANCE of
the FA core complex. FANCD2 interacts with FANCE through its N-terminus and residue
leucine 51 is critical for this interaction. This interaction then leads to the
monoubiquitination of FANCD2 by UBE2T and the recruitment of downstream DNA repair
factors.

....
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A.

B.
A.

Figure 17. Leucine 51 of FANCD2 in the crystal structure of the FANCD2-FANCI
complex. A. Crystal structure of FANCD2 in pink and FANCI in pink. The N-terminus of
FANCD2 can be seen in blue with leucine 51 highlighted in red. B. A close-up of the
structure of the N-terminus of FANCD2 with leucine 51 highlighted in red. PDB
downloaded from: http://www.rcsb.org/pdb/explore.do?structureId=3s4w - 3D image
created with Swiss-PdbViewer 4.1.0.

.....
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Figure 18. Leucine 51 is conserved across species. Aligned sequences of the first 60
amino acids of FANCD2 of Homo sapiens (human), Mus musculus (mouse), Sus scrofa
(pig), Gallus gallus (chicken), and Xenopus laevis (frog). Leucine 51 is marked by two red
arrows at the top and at the bottom. Sequences aligned using Clustal Omega
http://www.ebi.ac.uk/Tools/msa/clustalo/.
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A.

B.
A.

Figure 19. PD-20 cell line is sensitive to the cross-linker MMC while PD-20
complemented with WT FANCD2 is not. A. Colony formation on the plate after PD-20
and PD-20+FANCD2 have been treated with MMC for 7 days. Colonies form and grow in
the well that have PD-20+FANCD2 but not in the well with PD-20 cells. B. Graph depicting
the percentage of the cells that survived the MMC treatment. PD-20 cell survival drops at
10 nM of MMC.
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CHAPTER FOUR: INHIBITION OF UBE2T BY SMALL PEPTIDES

Rationale
The FA pathway regulates DNA repair in order to maintain genome
stability. The FA pathway is seen to be highly active in rapidly proliferating
tissue. 11 proteins from the FA pathway have increased mRNA levels in brain
tumors when compared to normal brain tissue [73]. Even though the FA
pathway has an important role in the cell’s genome integrity and it has been
seen to be upregulated in cancer cells, no specific inhibitor of the FA
pathway has been reported yet. An inhibitor of CDK1, which phosphorylates
BRCA1, has been shown to inhibit HR and make cells sensitive to the
chemotherapy treatment; this CDK1 inhibitor is still not specific enough in
order to be utilized as a therapeutic agent for cancer patients [74]. Cisplatin
is a commonly used chemotherapy drug, many cancers will become
resistance to cisplatin treatment. This resistance could be in part due to
upregulation the FA pathway, which is required to repair cross-links in the
cell and is highly active in cancer cells (figure 7, p.24-25) [75].
UBE2T is the E2 conjugating enzyme of the FA pathway and it binds to
FANCL, the E3 ligase unit of the FA core complex [53]. Cells that do not
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express UBE2T are sensitive to DNA damaging agents, which leads to
chromosomal breaks and genome instability [29]. The monoubiquitination of
FANCD2 by UBE2T is the key regulatory step of the FA pathway, if this
crucial step can be inhibited cells can become sensitive to cross-linking
agents like cisplatin [29]. We are currently studying the inhibition of UBE2T
by small peptides and its effect on the monoubiquitination of FANCD2. Dr.
Cai from the USF Chemistry department has previously found a γ-AApeptide
that inhibits STAT3’s interaction with DNA in cultured cells at a concentration
of 100 µM [76]. Using the same approach Dr. Cai provided us with peptides
that were designed to mimic the interphase in between UBE2T and FANCL
and in addition, he provided us peptides that have been picked from a
library and have been shown to interact with UBE2T in their initial UBE2T
interaction screen.
Experimental Design and Methods
GST Protein Purification
BL21 bacteria that had been transformed with pGEX-6P-1 expressing
the desired proteins (either FANCL-RING, UBE2T, or no protein) (GE
Healthcare) was inoculated in 50mL of media overnight at 37°C. The next
morning 250 mL of media was added to the culture. The culture was left to
incubate for two hours at 37°C. IPTG was then added to the culture to a final
concentration of 300µM and the culture was incubated for two more hours.
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The culture was spun at 5,000 rpm for seven minutes. The supernatant was
discarded. The pellet was re-suspended in GST buffer (150 mM NaCl, 20 mM
Tris pH 7.4, 0.5% triton, 0.1% EDTA) and sonicated (01, 01, 50%) for one
minute, the homogenate was then spun down at 20,000 rpm for 40 minutes.
The supernatant was incubated with 100 µL of glutathione beads (Sigma
Aldrich) overnight. The beads were washed with GST buffer four times and
the purified proteins were then ran in a SDS page gel and stained with
coomassie dye. In the case of UBE2T, the GST tag was then cleaved by
washing the beads with cleavage buffer (1 M tris pH 8, 5 M NaCl, 500 mM
EDTA, 1 M DTT, and 10% NP-40) and then incubating PreScission Protease
(GE Healthcare) overnight. The beads were then spun down and the
supernatant was collected. The purified UBE2T was then confirmed by
running it on a SDS gel and staining with coomassie. The amount of UBE2T
was then assessed by constructing a standard curve.
Screening of Small Peptides
Dr. Cai’s lab from the Chemistry Department at USF has synthesized
and provided to us several γ-AApeptides, which contain N-acylates-Naminoethyl amino acid units (figure 20) and are resistant to proteolytic
degradation [76]. Dr. Cai acquired a peptide library which was incubated
with purified UBE2T that we provided for him. After this incubation, the
beads were incubated with UBE2T antibody (Bethyl labs). Next the beads
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were incubated with Alexa Fluor 594 secondary antibody. Fluorescent beads
were then selected under a microscope. The peptides were cleaved off from
the beads, sequenced, and synthesized. Once we acquired the peptides we
dissolved in water to a final concentration of 6 mM.

Figure 20. Structure of a γ-AA peptide. (Adapted from Teng, et al., 2014 (73).

GST Pulldown
Once the GST proteins were purified (see method above), purified
UBE2T was incubated with either GST-FANCL-RING or GST in binding buffer
(50 mM NaCl, 10 mM Tris pH 7, and 0.25% NP-40) for four hours. The beads
were then washed with the binding buffer four times. 2X Laemmli buffer was
then added to the beads and they were boiled for 3 minutes. The
supernatant was run in a SDS gel. The membranes were then blotted with
UBE2T antibody (Bethyl labs).
In Vitro E2 Charging Assay
The E2 charging assay was performed by adding 500 nM of E1
(BostonBiochem), 10 µM of His-ubiquitin (Sigma Aldrich), and 0.8µM of
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UBE2T in reaction buffer (10 mM NaCl, 2 mM ATP, 10 mM tris pH 7.5, 1 mM
MgCl2 , 0.1 mM DTT). This reaction was then incubated at room temperature
for 45 minutes. The tubes then got added either 2X Laemmli buffer without
β-mercaptoethanol or Laemmli buffer with β-mercaptoethanol. The tubes
that contained β-mercaptoethanol were boiled for 3 minutes. The reaction
was then ran on a SDS gel. The membranes were blotted with ubiquitin
antibody (Millipore) and UBE2T antibody (Bethyl labs).
In Vivo FANCD2 monoubiquitination assay
HeLa cells were plated in a 6-well plate, once the cells reached a 70%
confluency the peptide inhibitors were added in different concentrations. The
next morning the media was removed and the cells were treated with 30 µJ ▪
m−2 UV irradiation. The media was added back on and the cells were
harvested five hours later. The cell extracts were ran on a SDS gel and
blotted for FANCD2 (Santa Cruz).
GST-FANCL-RING Pulls Down UBE2T In Vitro
We purified UBE2T by GST purification and PreScission protease
cleavage and the RING structure of FANCL by GST purification (figure 21).
GST-FANCL-RING and GST were incubated separately with UBE2T in order to
establish the interaction in between GST-FANCL-RING and UBE2T.
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We did see an enrichment in the interaction in between UBE2T and GSTFANCL-RING in vitro but not in between GST and UBE2T (figure 22). These
results show us that just the RING domain of FANCL is necessary for the
interaction with UBE2T in vitro and it gives us a good in vitro assay to test
the interaction of the proteins.
A

B

Figure 21. Purified GST, GST-FANCL-RING, and UBE2T. A. Coomassie stained gel
shows the purified GST and GST-FANCL-RING. B. Coomassie stained gel shows the
purified GST-UBE2T and the GST cleaved UBE2T.

Two Peptides Inhibit FANCD2 Monoubiquitination In Vivo
We wanted to test whether the peptides that we acquired from Dr.
Cai’s lab inhibited the monoubiquitination of FANCD2 in vivo. HeLa cells were
treated with the peptides for 16-17 hours. Afterwards the cells were
damaged with UV irradiation. Inhibition of the monoubiquitination of FANCD2
was seen with peptide 1 (i-1) and peptide 2 (i-2), but not with the others
(figure 23, panel A, lanes 5 and 8). It is important to note that these two
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peptides are the same molecular formula, peptides 2 (i-2) is the circular
conformation of peptide 1 (i-1) (figure 24).
A.

B.

C.

Figure 22. UBE2T interacts with GST-FANCL-RING in vitro. A. GST blot showing GST
and GST-FANCL-RING purified proteins in the GST pull down reactions B. UBE2T protein is
enriched in the reaction incubated with GST-FANCL-RING. C. Coomassie stained gel of
UBE2T that was added to the pull down reactions.

UBE2T is Ubiquitinated In Vitro but Not Inhibited by the Peptides
Once we established which inhibitors inhibited the monoubiquitination
of FANCD2 in vivo, we wanted to see if it was the UBE2T ubiquitin charging
step that was being inhibited by the two peptides that showed inhibition of
FANCD2 in our in vivo assay. We first set up the in vitro UBE2T charging
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assay and made sure that it worked properly (figure 25). Human purified E1
and UBE2T were incubated in the presence of ATP and ubiquitin for 45
minutes at room temperature. The results showed that both E1 and UBE2T

µM

Figure 23. i-1 and i-2 peptides inhibit the monoubiquitination of FANCD2 in
vivo. A. The monoubiquitination of FANCD2 is only inhibited by i-1 and i-2 but not by
the rest of the provided inhibitors. B. FANCD2 monoubiquitination with and without
damage without any inhibitor. C, E, D. Inhibitors 3 through 5 do not inhibit FANCD2
monoubiquitination.

were ubiquitinated in vitro. Reducing the reactions by the addition of 2X
laemmli buffer with β-mercaptoethanol and 3 minutes of boiling removed the
ubiquitin that is bound on the E1 by a thiol ester bond (figure 26). Once the
E2 charging assay was confirmed to work by repeating, we repeated the
reactions but added different concentrations (10 µM, 50 µM, 100 µM, or 150
µM) of i-1 or i-2. Neither i-1 nor i-2 inhibited the ubiquitin charging of
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UBE2T. These results lead us to the conclusion that these two inhibitors do
not disrupt the first step of the FA ubiquitin cascade.

Figure 24. Molecular structure of i-1 and i-2 peptides. The red asterisk in i2 depicts where the molecule was linearized.

Conclusion and Future Directions
UBE2T is located in 1q32.1, a region of chromosome one that has been
shown to be amplified in many cancers. Since UBE2T is essential for the
monoubiquitination of FANCD2 its inhibition in some cancers would, in
theory, be a valid combination-therapy for tumors that have acquired
cisplatin resistance. Despite the recognition of the FA pathway as a
therapeutic target, no specific FA pathway inhibitors have been developed up
to date [75].
Our study was conceptualized and designed with the goal that isolating
a specific inhibitor of the UBE2T-FANCL interaction would: 1) provide a
proof-of-principle that the critical E2-E3 reaction in the FA pathway can be a
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valid therapeutic target, 2) provide a useful pharmacologic tool that allows
‘acute’ inhibition of the FA pathway. For the latter point, current methods of
disrupting the FA pathway in cultured cells rely on RNAi-mediated
knockdown or, more recently, genome-editing knockout technology, which
often hampers researchers to investigate more direct functions of the FA
proteins that are independent of other changes associated with when the
gene is depleted (e.g. cell cycle).
Although our current effort so far was unsuccessful in identifying an
inhibitory peptide, we will continue to screen potential peptido-mimetics that
can specifically disrupt the UBE2T-FANCL interaction. We will need to further
optimize our assay condition that measures the interaction between UBE2T
and FANCL, in order to test the efficacy of these inhibitors in vitro. We may
further expand our efforts to screen for peptide inhibitors of the FANCEFANCD2 interaction, once we are able to purify large amounts of these
recombinant proteins that can be used for the peptide-selection procedures.
Our interaction analysis of FANCE-FANCD2 suggests that the FANCE-binding
surface of FANCD2 may not be an extensive flat-surface, but rather a small
hot spot within a helical area that may be sufficient for binding. This
possibility must be more rigorously tested with structural analysis of the two
purified proteins together; however, this can be a daunting task due to the
very low affinity between the two proteins.
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In order for the peptide-mimetic based inhibitor approach to be
successful, a few technical improvements have to be made; at this point we
have no way of determining that these peptide-mimetics are successfully
entering the cytoplasm and nucleus of the cultured cells, where they can
interact with their target proteins. Lipid-based delivery system can be
adapted for more efficient delivery of these peptides.
Consistent with previous reports we have established that UBE2T and
the RING domain of FANCL interact in vitro and that UBE2T gets charged
with ubiquitin in vitro [29]. Our in vitro ubiquitination and GST pulldown
assay will allow us to evaluate the efficacy of the small peptides selected in
Dr. Cai’s laboratory. We found that two of them, i-1 and i-2, inhibit the
monoubiquitination of FANCD2 in vivo. We are currently trying to set up and
optimize the GST-FANCL-RING pulldown assay in order to determine
whether the inhibitors disrupt the interaction between UBE2T and the RING
domain of FANCL (figure 27) in vitro.
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A.

B.
A.

Figure 25. UBE2T gets ubiquitinated in vitro. A. Anti-ubiquitin blot showing E1
ubiquitination in not reduced samples. The ubiquitination of UBE2T can be seen in
both figures. B. Ubiquitination of UBE2T can be seen by UBE2T blotting in the
reactions that contain all the needed components. Both red asterisks represent nonspecific bands.
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Figure 26. Inhibitors do not disrupt UBE2T charging. Anti-UBE2T blot shows that
the inhibitors do not disrupt the ubiquitination of UBE2T in vitro. Red asterisk indicates a
non-specific band.

......
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Figure 27. i-1 and i-2 might inhibit UBE2T-FANCL interaction. The inhibitors
provided by Dr. Cai might inhibit the interaction in between FANCL and UBE2T which
leads to the inhibition of the monoubiquitination of FANCD2 in vivo.
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